Beyond Air
Beyond Air is a commercial-stage medical device company that develops the LungFit family of inhaled nitric oxide delivery systems, which generate iNO on-demand from ambient room air using patented Ionizer technology, primarily serving hospital NICUs treating neonates with PPHN.
- Company typePublic
- Founded2011
- HeadquartersGarden City, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Beyond Air does
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company headquartered in Garden City, NY that develops the LungFit family of inhaled nitric oxide (iNO) delivery systems. The LungFit platform is built on patented Ionizer/Plasma Pulse Technology that generates therapeutic nitric oxide on-demand from ambient room air, eliminating the need for the 45-pound high-pressure gas cylinders used by legacy iNO systems. The flagship commercial product, LungFit PH, received FDA Premarket Approval in 2022 for treating term and near-term neonates with persistent pulmonary hypertension of the newborn (PPHN) in hospital NICU settings at concentrations of ≤80 ppm.
The company's pipeline extends the platform into higher-concentration indications and alternate settings. LungFit PRO targets community-acquired viral pneumonia and bronchiolitis (80-400 ppm) in hospitals; LungFit GO is an at-home system targeting nontuberculous mycobacteria (NTM) lung infections and COPD exacerbations; and LungFit PH II is a second-generation, transport-ready device under FDA PMA supplement review. The NO2 Smart Filter is a recurring 12-hour consumable used across the product family. Beyond Air generates revenue through direct hospital sales in the U.S., supported by national Group Purchasing Organization agreements with Vizient, Premier, Inc., and a top 3 GPO (effective April 2026), plus international distribution partnerships spanning 40 countries. The company also operates two biotech subsidiaries: Beyond Cancer, Ltd. (ultra-high concentration nitric oxide for solid tumors) and NeuroNOS Ltd. (nNOS inhibitors for autism spectrum disorder, Phelan-McDermid syndrome, and glioblastoma). Cumulative funding raised is approximately $88.85 million across equity, debt, and royalty financings, with up to $32 million in Streeterville Capital financing secured in November 2025 to support commercial expansion and a stated path to profitability by year-end 2026.
Beyond Air firmographics
Firmographics- Name
- Beyond Air
- Legal name
- Beyond Air, Inc.
- Website
- https://beyondair.net
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Beyond Air is a commercial-stage medical device company that develops the LungFit family of inhaled nitric oxide delivery systems, which generate iNO on-demand from ambient room air using patented Ionizer technology, primarily serving hospital NICUs treating neonates with PPHN.
- Ownership category
- akta.pro rank
Beyond Air industry classification
Industry- Product category
- Nitric Oxide Therapy Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (3254), Industrial Gas Manufacturing (32512)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers) (HLAHAGAK)
- akta.pro secondary industries
- Medical & Healthcare Gases (IMAEACAF), Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management (HLAKANAM), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
Keywords
Where Beyond Air is headquartered
LocationHeadquarters
- HQ city
- Garden City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Beyond Air business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel, Others
Revenue model
- LungFit PH Product Sales: Commercial sales of FDA-approved LungFit PH nitric oxide delivery systems and associated consumables/accessories to hospitals. The company reports quarterly revenue with strong year-over-year growth (105% in Q3 FY2026).
- Royalty Funding: $11.5 million royalty funding agreement based on commercial sales of LungFit PH product, providing non-dilutive capital based on product revenue.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Beyond Air product offering
Product offeringCore offering
Beyond Air develops, manufactures, and commercializes the LungFit family of FDA-cleared medical devices that generate inhaled nitric oxide (iNO) on-demand from ambient room air using patented Ionizer technology, eliminating the need for traditional high-pressure gas cylinders. The company's commercial product, LungFit PH, is sold to hospital neonatal intensive care units (NICUs) for treating persistent pulmonary hypertension of the newborn (PPHN), with pipeline systems (LungFit PRO, LungFit GO, LungFit PH II) targeting broader respiratory and infectious disease applications, plus biotech subsidiary programs in oncology and central nervous system therapeutics.
Product overview
Beyond Air is a commercial-stage medical device and biopharmaceutical company offering the LungFit family of products - a platform of tankless, on-demand nitric oxide generation systems that produce inhaled nitric oxide (iNO) directly from ambient air using patented Ionizer/Plasma Pulse Technology. The product family includes LungFit PH (FDA-approved for neonatal PPHN in hospital NICU settings, low-concentration ≤80 ppm), LungFit PRO (for hospital-based treatment of viral pneumonia and bronchiolitis, high-concentration 80-400 ppm), and LungFit GO (for at-home NTM and COPD treatment, high-concentration 80-400 ppm). The company also operates two biotech subsidiaries: NeuroNOS (developing nNOS inhibitors for autism, Phelan-McDermid syndrome, and Alzheimer's) and BeyondCancer (developing ultra-high concentration nitric oxide therapy for solid tumor cancer treatment). The company transitioned to a commercial-stage company following FDA approval of LungFit PH in 2022 and is pursuing international expansion with recent approvals in Australia and Europe.
Differentiator
Problem solved
Functional benefit
Brands
- LungFit: Family of nitric oxide delivery systems including LungFit PH (hospital NICU), LungFit PRO (hospital setting for viral pneumonia), and LungFit GO (at-home treatment for NTM)
- Beyond Cancer
- NeuroNOS
Products and services
- LungFit PH FDA-approved hospital NICU device that generates low-concentration inhaled nitric oxide (iNO ≤80 ppm) from room air using patented Ionizer technology to treat term and near-term neonates with hypoxic respiratory failure / persistent pulmonary hypertension of the newborn (PPHN).
- LungFit PRO Hospital-based system that generates high-concentration inhaled nitric oxide (80-400 ppm) using patented Ionizer technology for treating community-acquired viral pneumonia (including COVID-19) and bronchiolitis; investigational device limited by federal law to investigational use.
- LungFit GO At-home treatment system that generates high-concentration inhaled nitric oxide (80-400 ppm) for treating nontuberculous mycobacteria (NTM) lung infections and persistent lung infections in COPD patients; investigational device limited by federal law to investigational use.
- LungFit PH II Second-generation LungFit PH system, approximately half the weight of the first generation, with simplified operations, longer service intervals, air and ground transport compatibility, and an automated backup system; PMA supplement currently under FDA review.
- NO2 Smart Filter Disposable filter component used across the LungFit product family that reduces risk of NO2 exposure to patient and clinician, with integrated auto-purging; filter change required every 12 hours regardless of dose or flow.
Quantifiable outcome
- Revenue growth of 105% year-over-year to $2.2 million in Q3 FY2026
- +2 more outcomes
Companies that use Beyond Air
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Beyond Air technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Beyond Air partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, major and minor.
- Top 3 National Group Purchasing OrganizationcoreNational group purchasing agreement providing access to approximately 2,000 additional U.S. hospitals and health systems for LungFit PH inhaled nitric oxide therapy. Building on existing GPO relationships with Vizient and Premier, Inc.
- VizientcoreExisting GPO relationship providing access to Vizient-member hospitals for LungFit PH purchasing.
- Premier, Inc.coreExisting GPO relationship providing access to Premier-member hospitals for LungFit PH purchasing.
- XTL Biopharmaceuticals Ltd.majorBinding agreement for XTL to acquire 85% of Beyond Air's NeuroNOS subsidiary for 19.9% of XTL share capital, $1 million cash, and up to $32.5 million in milestone payments. Beyond Air retains 19.99% stake post-transaction. NeuroNOS developing treatments for Autism Spectrum Disorder and neuro-oncology.
- Getz HealthcarecoreRegional commercial partner for 10 Asian countries (excluding Japan), recognized as leading distributor of medical equipment, devices, and consumables in Asia Pacific. Partner for Australia market launch through TGA authorization.
- Vanderbilt University Medical CenterminorClinical partnership for high-dose inhaled nitric oxide research using LungFit PRO device in randomized clinical study for viral pneumonia (COVID-19).
- LifeSci AdvisorsminorInvestor relations support provided by LifeSci Advisors (Corey Davis, New York office). Manages investor communications and relations.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Beyond Air competitors and assessment
Company assessmentDirect peers
- Vapotherm: Vapotherm develops high-flow nasal cannula respiratory therapy systems for neonates and adults in respiratory distress. Comparable as a respiratory gas-delivery device vendor targeting similar NICU and hospital respiratory customers, though using a different gas-delivery mechanism.
- Mallinckrodt plc: Mallinckrodt markets INOmax, the incumbent cylinder-based inhaled nitric oxide delivery system for neonatal respiratory failure. Directly comparable as the established iNO therapy provider to the same hospital NICU customer base that Beyond Air's LungFit PH targets.
Broad incumbents
- Linde plc: Linde is the global industrial gas incumbent and supplies medical-grade nitric oxide and other gases to hospitals, including through cylinder distribution. Comparable because Beyond Air's LungFit directly displaces the cylinder supply chain that Linde and its peers (Air Liquide, Air Products) operate.
- ResMed: ResMed is a leading manufacturer of respiratory care devices for sleep apnea, COPD, and hospital ventilation. Comparable as a respiratory device incumbent whose hospital and home-care sales channels overlap with the customer base Beyond Air is building for LungFit PH and LungFit GO.
- Getinge (Maquet): Getinge (including Maquet) manufactures ventilators and respiratory care equipment for hospital ICUs and NICUs. Comparable as an established supplier of respiratory care capital equipment to the same hospital procurement channels that Beyond Air accesses via GPOs.
- Drägerwerk: Dräger is a broad medical technology incumbent with ventilator and anesthesia gas delivery systems used in NICUs. Comparable as a supplier of respiratory and gas-delivery equipment to the same hospital customer base, though its portfolio spans far beyond nitric oxide.
- Air Liquide: Air Liquide manufactures and distributes medical and industrial gases including nitric oxide cylinders to hospitals worldwide. Comparable as a supplier of the cylinder-based iNO delivery infrastructure that Beyond Air's tankless platform targets to displace.
Others
- Masimo: Masimo develops patient monitoring and pulse oximetry technologies widely used in NICU and ICU settings alongside inhaled nitric oxide therapy. Comparable as a NICU-adjacent technology supplier whose installed base overlaps with the clinical workflow into which LungFit systems integrate.
Emerging players
- Bellerophon Therapeutics: Bellerophon develops INOpulse, a pulsatile nitric oxide delivery system targeting pulmonary hypertension in COPD and other indications. Directly comparable as a competing iNO platform pursuing adjacent respiratory indications, though with a different delivery mechanism.
- Inogen: Inogen develops portable oxygen concentrators for home and ambulatory use. Comparable as a respiratory home-care device company pursuing a similar 'tankless / on-demand' displacement thesis versus traditional cylinder delivery for chronic respiratory patients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Beyond Air social profiles
Digital presenceBeyond Air compliance and trust
Trust signalCompliance3 records
Beyond Air financial estimates
Financial estimateRevenue estimate
Valuation estimate
Beyond Air leadership team
Management profileNumber of profiles
Profiles9 records
Beyond Air subsidiaries and ownership
Company hierarchySubsidiaries2 records
Beyond Air funding detail
Funding detailFunding overview
Funding rounds12 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Beyond Air M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Beyond Air
What does Beyond Air do?
Beyond Air develops, manufactures, and commercializes the LungFit family of FDA-cleared medical devices that generate inhaled nitric oxide (iNO) on-demand from ambient room air using patented Ionizer technology, eliminating the need for traditional high-pressure gas cylinders. The company's commercial product, LungFit PH, is sold to hospital neonatal intensive care units (NICUs) for treating persistent pulmonary hypertension of the newborn (PPHN), with pipeline systems (LungFit PRO, LungFit GO, LungFit PH II) targeting broader respiratory and infectious disease applications, plus biotech subsidiary programs in oncology and central nervous system therapeutics.
Is Beyond Air a public or private company?
Beyond Air is a public company. It is classified as public and is currently operating.
When was Beyond Air founded?
Beyond Air was founded in 2011. It employs 11 to 50 people.
Where is Beyond Air based?
Beyond Air is headquartered in Garden City, United States, in the North America region.
How does Beyond Air make money?
Two revenue lines are on record. LungFit PH Product Sales are the primary driver. The others are royalty Funding.
Who are Beyond Air's main competitors?
Direct peers on record are Vapotherm and Mallinckrodt plc. Broad incumbents are Linde plc, ResMed, Getinge (Maquet), Drägerwerk and Air Liquide. Masimo is listed as an others. Emerging players are Bellerophon Therapeutics and Inogen.
Does Beyond Air have an API?
No public API is recorded for Beyond Air.
What industry is Beyond Air in?
Beyond Air's product category is Nitric Oxide Therapy Medical Devices. Its primary akta.pro industry code is HLAHAGAK, Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers), with a secondary code of IMAEACAF, Medical & Healthcare Gases. Its NAICS code is 339113 and its SIC code is 3841.